Cargando…

Neprilysin activity is increased in metabolic dysfunction-associated steatotic liver disease and normalizes after bariatric surgery or GLP-1 therapy

Inhibitors of neprilysin improve glycemia in patients with heart failure and type 2 diabetes (T2D). The effect of weight loss by diet, surgery, or pharmacotherapy on neprilysin activity (NEPa) is unknown. We investigated circulating NEPa and neprilysin protein concentrations in obesity, T2D, metabol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kjeldsen, Sasha A.S., Gluud, Lise L., Werge, Mikkel P., Pedersen, Julie S., Bendtsen, Flemming, Alexiadou, Kleopatra, Tan, Tricia, Torekov, Signe S., Iepsen, Eva W., Jensen, Nicole J., Richter, Michael M., Goetze, Jens P., Rungby, Jørgen, Hartmann, Bolette, Holst, Jens J., Holst, Birgitte, Holt, Joachim, Gustafsson, Finn, Madsbad, Sten, Svane, Maria S., Bojsen-Møller, Kirstine N., Wewer Albrechtsen, Nicolai J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638073/ https://www.ncbi.nlm.nih.gov/pubmed/37953952 http://dx.doi.org/10.1016/j.isci.2023.108190

Ejemplares similares

SAT032 Circulating Neprilysin Activity Is Increased In Type 2 Diabetes And Fatty Liver Disease, And Reduces Following Bariatric Surgery And Liraglutide Therapy
por: Sampson Kjeldsen, Sasha Alexandra, et al.
Publicado: (2023)

Acute effects on glucose tolerance by neprilysin inhibition in patients with type 2 diabetes
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2022)

Proteomics reveals the effects of sustained weight loss on the human plasma proteome
por: Geyer, Philipp E, et al.
Publicado: (2016)

Effects of Manipulating Circulating Bile Acid Concentrations on Postprandial GLP-1 Secretion and Glucose Metabolism After Roux-en-Y Gastric Bypass
por: Jonsson, Isabella, et al.
Publicado: (2021)

Treatment with liraglutide may improve markers of CVD reflected by reduced levels of apoB
por: Engelbrechtsen, L., et al.
Publicado: (2017)

Methods and Guidelines for Measurement of Glucagon in Plasma
por: Holst, Jens J., et al.
Publicado: (2019)

Mechanisms in bariatric surgery: Gut hormones, diabetes resolution, and weight loss()
por: Holst, Jens Juul, et al.
Publicado: (2018)

Health care professionals from developing countries report educational benefits after an online diabetes course
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Neprilysin Inhibition Increases Glucagon Levels in Humans and Mice With Potential Effects on Amino Acid Metabolism
por: Kjeldsen, Sasha A S, et al.
Publicado: (2021)

Sustained Improvements in Glucose Metabolism Late After Roux-En-Y Gastric Bypass Surgery in Patients with and Without Preoperative Diabetes
por: Jørgensen, Nils B., et al.
Publicado: (2019)

Patients With Long-QT Syndrome Caused by Impaired hERG-Encoded K(v)11.1 Potassium Channel Have Exaggerated Endocrine Pancreatic and Incretin Function Associated With Reactive Hypoglycemia
por: Hyltén-Cavallius, Louise, et al.
Publicado: (2017)

Nonalcoholic Fatty Liver Disease Impairs the Liver–Alpha Cell Axis Independent of Hepatic Inflammation and Fibrosis
por: Pedersen, Julie Steen, et al.
Publicado: (2020)

The liver–alpha cell axis associates with liver fat and insulin resistance: a validation study in women with non-steatotic liver fat levels
por: Gar, Christina, et al.
Publicado: (2020)

Effect of Meal Texture on Postprandial Glucose Excursions and Gut Hormones After Roux-en-Y Gastric Bypass and Sleeve Gastrectomy
por: Hedbäck, Nora, et al.
Publicado: (2022)

Primary weight loss failure after Roux-en-Y gastric bypass is characterized by impaired gut-hormone mediated regulation of food intake
por: Bojsen-Møller, Kirstine Nyvold, et al.
Publicado: (2023)

Chenodeoxycholic acid stimulates glucagon‐like peptide‐1 secretion in patients after Roux‐en‐Y gastric bypass
por: Nielsen, Signe, et al.
Publicado: (2017)

Treatment with a GLP-1 receptor agonist diminishes the decrease in free plasma leptin during maintenance of weight loss
por: Iepsen, E W, et al.
Publicado: (2015)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
por: Iepsen, Eva W., et al.
Publicado: (2020)

Secretin release after Roux-en-Y gastric bypass reveals a population of glucose-sensitive S cells in distal small intestine
por: Modvig, Ida M., et al.
Publicado: (2020)

The Role of the Transsulfuration Pathway in Non-Alcoholic Fatty Liver Disease
por: Werge, Mikkel Parsberg, et al.
Publicado: (2021)

Stability of glucagon-like peptide 1 and glucagon in human plasma
por: Wewer Albrechtsen, Nicolai J, et al.
Publicado: (2015)

The intestinal distribution pattern of appetite- and glucose regulatory peptides in mice, rats and pigs
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Inability of Some Commercial Assays to Measure Suppression of Glucagon Secretion
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2016)

Glucagon Receptor Signaling and Lipid Metabolism
por: Galsgaard, Katrine D., et al.
Publicado: (2019)

Glucagon Receptor Signaling and Glucagon Resistance
por: Janah, Lina, et al.
Publicado: (2019)

A Potential Role for Endogenous Glucagon in Preventing Post-Bariatric Hypoglycemia
por: Lobato, Carolina B., et al.
Publicado: (2020)

GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass
por: Guimarães, Marta, et al.
Publicado: (2015)

Plasma levels of glucagon but not GLP-1 are elevated in response to inflammation in humans
por: Modrzynska, Justyna, et al.
Publicado: (2021)

The Effect of a Subcutaneous Infusion of GLP-1, OXM, and PYY on Energy Intake and Expenditure in Obese Volunteers
por: Tan, Tricia, et al.
Publicado: (2017)

Effects of Roux-en-Y Gastric Bypass and Sleeve Gastrectomy on Non-Alcoholic Fatty Liver Disease: A 12-Month Follow-Up Study with Paired Liver Biopsies
por: Pedersen, Julie Steen, et al.
Publicado: (2021)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Proglucagon peptide secretion profiles in type 2 diabetes before and after bariatric surgery: 1-year prospective study
por: Alexiadou, Kleopatra, et al.
Publicado: (2020)

Glucagon‐like peptide‐1 acutely affects renal blood flow and urinary flow rate in spontaneously hypertensive rats despite significantly reduced renal expression of GLP‐1 receptors
por: Ronn, Jonas, et al.
Publicado: (2017)

On the relationship between glucose absorption and glucose‐stimulated secretion of GLP‐1, neurotensin, and PYY from different intestinal segments in the rat
por: Kuhre, Rune E., et al.
Publicado: (2017)

Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides
por: Challis, Benjamin G, et al.
Publicado: (2015)

Glucagon‐like peptide‐1 elicits vasodilation in adipose tissue and skeletal muscle in healthy men
por: Asmar, Ali, et al.
Publicado: (2017)

Markers of Glucagon Resistance Improve With Reductions in Hepatic Steatosis and Body Weight in Type 2 Diabetes
por: Kjeldsen, Sasha A S, et al.
Publicado: (2023)

Circulating Glucagon 1-61 Regulates Blood Glucose by Increasing Insulin Secretion and Hepatic Glucose Production
por: Wewer Albrechtsen, Nicolai J., et al.
Publicado: (2017)

Evaluation of commercially available glucagon receptor antibodies and glucagon receptor expression
por: Bomholt, Anna Billeschou, et al.
Publicado: (2022)

Exaggerated Glucagon-Like Peptide 1 Response Is Important for Improved β-Cell Function and Glucose Tolerance After Roux-en-Y Gastric Bypass in Patients With Type 2 Diabetes
por: Jørgensen, Nils B., et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_0q7oo83304ntpo2039g9tqq8m6